Last10K.com

Accentia Biopharmaceuticals Inc (1310094) SEC Filing 10-K Annual report for the fiscal year ending Sunday, September 30, 2012

Accentia Biopharmaceuticals Inc

HISTORY TOOLS
CIK: 1310094
Document and Entity Information (USD $)
 12 Months Ended
Sep. 30, 2012
Nov. 30, 2012
Mar. 30, 2012
Document and Entity Information [Abstract]      
Entity Registrant Name ACCENTIA BIOPHARMACEUTICALS INC    
Entity Central Index Key 0001310094    
Document Type 10-K    
Document Period End Date Sep. 30, 2012    
Amendment Flag false    
Document Fiscal Year Focus 2012    
Document Fiscal Period Focus FY    
Current Fiscal Year End Date --09-30    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Filer Category Smaller Reporting Company    
Entity Public Float     $ 26,700,000
Entity Common Stock Shares Outstanding   89,755,901  

View differences made from one year to another to evaluate Accentia Biopharmaceuticals Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Accentia Biopharmaceuticals Inc.

Continue

Assess how Accentia Biopharmaceuticals Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Accentia Biopharmaceuticals Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2012 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (parenthetical)
Consolidated Statement Of Stockholders' Deficit
Consolidated Statements Of Cash Flows
Consolidated Statements Of Operations
Commitments And Contingencies
Commitments And Contingencies (details)
Convertible Long Term Debt (details)
Convertible Long-term Debt
Convertible Long-term Debt (details 1)
Convertible Long-term Debt (details Textual)
Convertible Long-term Debt (tables)
Derivative Liabilities
Derivative Liabilities (details 1)
Derivative Liabilities (details 2)
Derivative Liabilities (details)
Derivative Liabilities (tables)
Description Of The Company
Description Of The Company (details)
Discontinued Operations
Discontinued Operations (details 1)
Discontinued Operations (details Textual)
Discontinued Operations (details)
Discontinued Operations (tables)
Employee Benefit Plan
Employee Benefit Plan (details Textual)
Furniture Equipment And Leasehold Improvements
Furniture Equipment And Leasehold Improvements (details)
Furniture Equipment And Leasehold Improvements (tables)
Income Taxes
Income Taxes (details 1)
Income Taxes (details 2)
Income Taxes (details Textual)
Income Taxes (details)
Income Taxes (tables)
Intangible Assets
Intangible Assets (details 1)
Intangible Assets (details)
Intangible Assets (tables)
Inventories
Inventories (details)
Inventories (tables)
Liquidity
Liquidity (details Textual)
Liquidity (details)
Liquidity (tables)
Note Payable
Note Payable (details)
Other Long-term Debt
Other Long-term Debt (details 1)
Other Long-term Debt (details Textual)
Other Long-term Debt (details)
Other Long-term Debt (tables)
Related Party Transactions
Related Party Transactions (details)
Reserve For Unresolved Claims
Reserve For Unresolved Claims (details Textual)
Significant Accounting Policies And Consolidation Policy
Significant Accounting Policies And Consolidation Policy (details 1)
Significant Accounting Policies And Consolidation Policy (details 2)
Significant Accounting Policies And Consolidation Policy (details Textual)
Significant Accounting Policies And Consolidation Policy (details)
Significant Accounting Policies And Consolidation Policy (policies)
Significant Accounting Policies And Consolidation Policy (tables)
Stockholders' Equity
Stockholders' Equity (details 1)
Stockholders' Equity (details 2)
Stockholders' Equity (details 3)
Stockholders' Equity (details Textual)
Stockholders' Equity (details)
Stockholders' Equity (tables)
Subsequent Events
Subsequent Events (details)
Unbilled Receivables And Unearned Revenues
Unbilled Receivables And Unearned Revenues (details 1)
Unbilled Receivables And Unearned Revenues (details)
Unbilled Receivables And Unearned Revenues (tables)
Variable Interest Entities
Variable Interest Entities (details)
CIK: 1310094
Form Type: 10-K Annual Report
Accession Number: 0001193125-12-514944
Submitted to the SEC: Wed Dec 26 2012 4:35:32 PM EST
Accepted by the SEC: Wed Dec 26 2012
Period: Sunday, September 30, 2012
Industry: Pharmaceutical Preparations

External Resources:

Bookmark the Permalink:
https://last10k.com/sec-filings/1310094/0001193125-12-514944.htm